Asset sale vs share sale for a Canadian pharmacy

One of the most consequential decisions you will make when selling your pharmacy has nothing to do with price, timing, or finding the right buyer.

It is how you structure the transaction itself.

Every pharmacy sale in Canada happens through one of two legal structures: an asset sale or a share sale. The structure you choose affects your tax bill, your liability exposure after closing, the complexity of the transaction, and sometimes whether the deal closes at all.

Most pharmacy owners do not understand the difference until they are deep in negotiations. By then, changing course is difficult or impossible. Sellers push for share sales to minimize taxes. Buyers insist on asset sales to limit liability. The structure becomes a negotiation point that can make or break deals.

This guide explains exactly how the asset sale vs share sale decision works for Canadian pharmacy transactions, the advantages and disadvantages of each, the tax implications, and how to decide which structure makes sense for your situation.

Quick summary: what you will learn

• The fundamental legal difference between asset and share sales
• Why many pharmacy buyers strongly prefer asset sales (in our experience)
• How share sales can save sellers significant taxes through the Lifetime Capital Gains Exemption
• Liability and risk differences that matter after closing
• Administrative complexity and third-party consent requirements
• How to negotiate structure as part of your deal terms

What is an asset sale?

In an asset sale, the buyer purchases specific assets of your pharmacy business rather than buying your corporation itself. The assets typically include:

• Prescription files (patient records and refill history)
• Goodwill and trade name
• Inventory (at cost, counted at closing)
• Equipment and fixtures (dispensing systems, shelving, computers)
• Leasehold improvements
• Intellectual property (if any)

The buyer does not acquire your corporate entity. Your pharmacy corporation continues to exist after the sale. It simply no longer owns the operating assets. You (the seller) remain responsible for winding down the corporation, paying any remaining liabilities, and eventually dissolving it.

The buyer typically forms a new corporation or uses an existing entity to purchase the assets. They start with clean books and generally leave the seller’s historical liabilities behind, subject to the exceptions explained below.

Example: You own “Maple Pharmacy Ltd.” The buyer forms “New Pharmacy Corp.” and purchases the prescription files, inventory, and equipment from Maple Pharmacy Ltd. for $1.5 million. Maple Pharmacy Ltd. receives the cash but continues to exist (with you as the shareholder) until you dissolve it after settling any remaining obligations.

What is a share sale?

In a share sale, the buyer purchases all the shares of your pharmacy corporation. They acquire the entire legal entity, including all its assets and all its liabilities.

After closing, the corporation continues operating under new ownership. The corporate name, tax numbers, bank accounts, contracts, and licences stay with the corporation, and only the shareholder changes, subject to the consent and regulatory requirements described next.

From an operational perspective, share sales can look seamless. Supplier contracts, lease agreements, pharmacy software licences, and third-party billing arrangements do not need to be assigned because the contracting party (your corporation) has not changed. That does not mean no approval is needed: many leases, banner agreements and other contracts have change of control clauses that require consent or notice when the shares are sold, and pharmacy colleges have their own requirements when the owners of a pharmacy corporation change.

Example: You own 100% of the shares of “Maple Pharmacy Ltd.” The buyer purchases all your shares for $1.5 million. Maple Pharmacy Ltd. continues to exist exactly as before, but now the buyer owns the shares instead of you.

Why buyers strongly prefer asset sales

Asset sales are widely considered the safer, more buyer-friendly structure for pharmacy acquisitions. In our experience, most pharmacy sales in Canada are structured as asset sales, largely because they offer buyers significant liability protection.

Liability protection

The primary advantage for buyers is that they can generally choose which assets and which contractual liabilities they take on, so most of the seller’s historical liabilities stay with the seller’s corporation. That protection is strong but not absolute, as explained below.

Liabilities that generally stay with the seller in an asset sale:

• Past tax debts or unfiled returns
• Outstanding lawsuits or legal claims
• Employee issues (wrongful dismissal claims, unpaid wages)
• Supplier debts or disputed invoices
• Regulatory violations or college of pharmacy sanctions
• Third-party billing errors or insurance clawbacks
• Privacy breaches (under Alberta’s Health Information Act, Ontario’s PHIPA, BC’s PIPA, or other applicable privacy law)
• Narcotics discrepancies or controlled substance tracking issues
• Undisclosed environmental contamination

In a pharmacy context, these risks are not theoretical. Regulatory compliance issues are common. Third-party insurers regularly audit and claw back payments for prescriptions dispensed years earlier. Privacy laws carry significant penalties. Narcotics tracking errors can result in college investigations.

An asset buyer generally leaves most of this behind. If your college of pharmacy discovers a dispensing error from two years ago after the sale closes, that is generally your responsibility as the seller, not the buyer’s.

What can still follow an asset buyer. Some obligations attach to the business or the assets rather than the seller’s corporation, so an asset buyer still needs to check:

• Employees who continue: in several provinces, employment of staff who move to the buyer is treated as continuous (in BC, under section 97 of the Employment Standards Act), so their service with the seller can count toward notice and severance with the buyer.
• Some tax liabilities: certain provincial sales tax rules (BC PST, for example) can make a buyer liable for the seller’s unpaid tax unless a clearance certificate is obtained or funds are held back. Ask your lawyer which clearance steps apply.
• Liens and security interests: registered security against the assets (from the seller’s bank or suppliers) stays with the assets until it is discharged, so search the registry and get discharges at closing.
• Contracts and licences: contracts you want to keep may need the other party’s consent to assign, and regulatory duties apply to you as the new operator from day one.

Selective asset acquisition

Asset sales allow buyers to cherry-pick what they want and exclude what they do not.

Common exclusions in pharmacy asset sales:

• Outdated or broken equipment
• Slow-moving or obsolete inventory
• Accounts receivable (the seller keeps these and collects them)
• Non-core business lines the buyer does not want
• Employees the buyer chooses not to hire (subject to employment law, which can still create obligations)
• Liabilities the buyer does not agree to assume (subject to the exceptions above)

Example: Your pharmacy has $350,000 in inventory, but $40,000 is near-expiry or slow-moving product. In an asset sale, the buyer can negotiate to purchase only $310,000 of current, saleable inventory and leave the rest with you.

Greater control over inventory valuation

Inventory represents a significant portion of pharmacy transaction value, in our experience often $100,000 to $400,000. Asset sales give buyers more control over what they pay for.

The purchase agreement commonly specifies (all of these are negotiated, not standard terms):

• A joint physical count at closing
• Exclusion of expired or damaged products
• Reduced payment for near-expiry items (for example, products expiring within 3 to 6 months)
• Separate valuation for narcotics and controlled substances
• Verification against current wholesaler cost

This ensures buyers pay only for real, usable inventory value rather than accepting a book value that may include write-offs the seller has not yet recorded.

Cleaner operational transition

Despite requiring more paperwork, asset sales often lead to smoother long-term operations because the buyer starts fresh.

The buyer establishes:

• A new corporate entity with clean accounting records
• New employee contracts and benefit structures
• New supplier accounts and pricing agreements
• New banking relationships
• A new pharmacy licence or accreditation issued through the college’s process for the new owner, and a fresh regulatory compliance history
• Updated software configurations and workflows

While the buyer must handle lease assignments, the pharmacy licence application, and third-party billing enrolment, these administrative steps force verification that everything is in order. Problems surface and get resolved before closing rather than appearing as surprises months later.

Why sellers often prefer share sales

From a seller’s perspective, share sales offer one compelling advantage: tax efficiency.

Lifetime Capital Gains Exemption (LCGE)

The LCGE is the primary reason many pharmacy owners want share sales. As of 2026, the Lifetime Capital Gains Exemption allows Canadian residents to shelter up to $1,275,000 in capital gains from the sale of qualified small business corporation shares.

This section is general information, not legal or tax advice; your accountant needs to confirm how the rules apply to you.

How it works: if you sell the shares of your pharmacy corporation and they qualify as qualified small business corporation shares, up to $1,275,000 of your gain can be sheltered from regular income tax, provided you have not used your exemption before. The remaining gain (if any) is taxed at capital gains rates (a 50% inclusion rate as of 2026, though this rate can change). Alternative minimum tax (AMT) can still apply in the year of sale even when the exemption shelters the gain.

Illustrative example. You bought your pharmacy 20 years ago for $200,000. You sell the shares today for $1,500,000. The figures below assume you have your full, unused LCGE, a 50% marginal tax rate, and they show regular income tax only (AMT is not calculated).

Your actual cash tax in the year of sale may be higher if AMT applies (AMT can often be recovered in later years), so get an individual calculation.

Compare this to an asset sale, where your corporation is taxed on the sale and you are taxed again when you take the money out, without access to the LCGE. The difference can be significant, but it depends on many facts, so have your accountant model both structures before you decide.

Qualification requirements for the LCGE

Not all pharmacy corporations qualify. Based on the CRA’s definition of qualified small business corporation shares, the main tests are:

• The corporation must be a Canadian-controlled private corporation (CCPC)
• At the time of sale, all or substantially all (generally 90% or more) of the fair market value of the corporation’s assets must be used mainly in an active business carried on primarily in Canada, or be shares or debt of connected small business corporations that meet the rules
• Throughout the 24 months before the sale, more than 50% of the fair market value of the corporation’s assets must have met that same test (special rules apply to holdings in connected corporations)
• Throughout the 24 months before the sale, the shares must not have been owned by anyone other than you or a person or partnership related to you

Most active pharmacy corporations qualify, but if you have accumulated significant passive investments inside your pharmacy corporation (like a large GIC portfolio or real estate holdings), you may not meet the 90% test at the time of sale.

Critical planning point: Consult with your accountant at least 24 months before selling to ensure your corporation structure qualifies for the LCGE. Purifying the corporation (moving passive assets out) takes time and must be done properly.

Simpler contractual transfer

Share sales avoid the need to assign many contracts because the corporation (the contracting party) does not change.

Contracts that generally stay in place in a share sale (subject to any change of control terms):

• Commercial lease (the corporation remains the tenant)
• Supplier agreements (the corporation remains the customer)
• Pharmacy software licences (same licensee)
• Third-party billing arrangements (same pharmacy entity)
• Insurance policies (same insured)

This can reduce administrative burden. It does not remove consent rights the contracts themselves contain: many commercial leases, banner and franchise agreements, and some supplier and software contracts treat a sale of shares (a change of control) like an assignment and require consent or notice, which gives landlords, franchisors or suppliers the same chance to ask for new terms. Pharmacy colleges also have requirements when the owners of a licensed pharmacy corporation change (the Alberta College of Pharmacy, for example, covers changes involving major voting shareholders). Check each contract and your college’s rules early. Our article on how a pharmacy lease changes hands covers assignment, change of control and a new lease in detail.

Potential price leverage

Because sellers often strongly prefer share sales for tax reasons, this can become a negotiation tool.

If a buyer is willing to accept a share purchase (taking on the additional risk), the seller might agree to:

• A slightly lower purchase price
• More favourable working capital adjustments
• Vendor take-back financing, where the seller provides part of the purchase price as a loan
• A longer transition support period
• Stronger indemnity provisions to protect the buyer

The seller’s tax savings can be large enough that giving up some price (for example, $50,000 to $100,000) or offering better terms still results in more net cash than an asset sale at full price. Whether it does in your case is something your accountant needs to calculate.

Illustrative negotiation scenario: when structure drives price

The interplay between transaction structure and price often plays out in predictable patterns. Here is how a negotiation might unfold when buyer and seller have opposing preferences. This is an illustrative scenario: the names are invented and the figures are assumptions chosen to show the mechanics, not results from a real file.

The setup. Sarah owns a successful independent pharmacy in Ontario generating $400,000 in normalized EBITDA. Based on comparable sales, the fair market value is approximately $2,000,000 (a 5x EBITDA multiple) in an asset sale, with inventory paid separately at cost on a closing count.

For this illustration, assume Sarah’s accountant has modelled both structures (price allocation, her cost base, corporate and personal tax, LCGE eligibility and AMT) and concluded that a share sale at $2,000,000 would leave her about $280,000 more after tax than an asset sale at $2,000,000. This is a substantial difference that would significantly impact her retirement plans.

David, a pharmacist buyer, has his financing pre-approved through his bank. However, his bank has made it clear they strongly prefer asset purchases due to liability concerns and have built their loan structure around acquiring assets, not shares.

Round 1: initial positions. Sarah lists the pharmacy at $2,000,000 as a share sale. David submits a Letter of Intent at $1,950,000 as an asset sale.

Sarah counters: “I understand your preference for an asset sale, but that structure will cost me $280,000 in additional taxes. I’m willing to accept an asset sale, but the price needs to be $2,280,000 to compensate for my tax liability.”

David responds: “I appreciate your tax situation, but the market value is $2,000,000. I cannot justify paying $280,000 more just to cover your tax bill. That is not how valuations work.”

Stalemate.

Round 2: finding middle ground. Sarah’s broker suggests a compromise approach. Sarah reconsiders her position and proposes:

“David, I recognize that asking you to cover my entire tax difference is unrealistic. Here’s what I propose: I’ll accept the asset sale structure at $2,100,000, which is $100,000 above market value. That way we share the tax burden. In exchange, I’ll provide three months of transition support instead of the four weeks in my original offer, and I’ll stay on part-time to ensure continuity.”

David counters: “I understand the compromise, but my bank’s valuation still shows $2,000,000 for the business. Paying $100,000 over market creates a financing gap. However, I’m willing to meet you halfway. I’ll pay $2,050,000 as an asset sale, which is $50,000 above market. You absorb the majority of the tax impact, but I recognize your situation and compensate you partially.”

Round 3: the final structure. After further discussion, they agree on $2,050,000 as an asset purchase with the following terms:

• Purchase price: $2,050,000 (asset sale), with inventory paid separately at cost on the closing count
• Seller transition support: 8 weeks full-time, then 8 weeks part-time (20 hours per week)
• Seller consulting availability: 6 months of on-call support for questions
• Near-expiry inventory: about $60,000 (at cost) of stock is within 6 months of expiry. David’s first offer was 50% of cost for these items; he agrees to pay 75% of cost instead. That is $45,000 instead of $30,000, so $15,000 more to Sarah.

The math for Sarah (seller), illustrative:

The real gap is larger than $215,000 because the $65,000 is itself taxed. Both extra amounts are received by her corporation and taxed there, then taxed again when she takes the money out. The inventory amount is business income to her corporation, not a capital gain: what a business receives for inventory is income, offset by the inventory’s cost, so the extra $15,000 raises her corporation’s taxable business income (here it reduces the loss on stock sold below cost). Her accountant would compute the exact after tax figure. Either way, she absorbs most of the structure cost but receives meaningful help.

The math for David (buyer), illustrative:

• Pays $50,000 above market value for the business
• Pays $15,000 more for near-expiry inventory than his first offer. This is an extra cost to David, not a benefit. (For tax purposes, what he pays for inventory becomes his cost of goods sold, deducted as the stock is sold or written off.)
• Gains exceptional transition support, which he values at about $25,000 in avoided complications (his own assumption)
• Net premium over market: about $50,000 + $15,000 minus $25,000 = $40,000 before tax effects
• Gets his preferred structure with bank approval and the liability protection of an asset purchase

The outcome. Both parties compromise. Sarah does not get her full tax burden covered, but David acknowledges her situation by moving on price and on the inventory terms. David pays above market but gets his required structure and support that reduces his risk. The deal closes successfully.

A note on allocation: within a fixed total price, putting more of the price on inventory rather than goodwill usually helps the buyer (inventory cost is deducted as it is sold, while goodwill is written off slowly) and costs the seller (inventory proceeds above cost are fully taxable business income, while goodwill proceeds can be partly capital gain). That is why the price allocation is negotiated and should be reviewed by both accountants.

Key lesson: When structure preferences conflict, creative negotiation can bridge the gap. Sellers should not expect buyers to absorb 100% of their tax burden from structure choices. Buyers should recognize that sellers face real financial consequences and some accommodation may be necessary to close the deal. The most successful negotiations use non-price terms (transition support, inventory valuation methods, payment timing) to create additional value that makes the compromise acceptable.

The risks buyers face in share sales

While share sales offer administrative simplicity, buyers inherit significant risks.

The corporation’s liabilities come with it

The corporation remains responsible for all its liabilities, including unknown or undisclosed ones, and the buyer now owns that corporation. The buyer is not usually personally liable for the corporation’s debts (unless they sign personal guarantees), but those liabilities come out of the business they paid for.

Common hidden liabilities in pharmacy share sales:

• College of pharmacy violations not yet discovered or reported
• Incorrect third-party billing that triggers future clawbacks
• Privacy breaches not yet reported to regulators (under Alberta’s Health Information Act, Ontario’s PHIPA, BC’s PIPA, or other applicable law)
• Narcotics inventory discrepancies that appear during the next inspection
• Employee claims (wrongful dismissal, human rights complaints)
• Unpaid or incorrectly filed taxes
• Supplier disputes or quality issues with past orders
• Contract breaches the seller did not disclose

Even with representations and warranties in the purchase agreement, enforcing them after closing can be difficult. The seller might be unavailable, insolvent, or dispute the claim. Litigation is expensive and uncertain.

Due diligence intensity

Because the corporation’s liabilities stay with it in a share sale, buyers must conduct far more extensive due diligence.

Additional due diligence in share sales:

• Complete review of corporate minute books and resolutions
• Verification of all historical tax filings (corporate and GST/HST)
• Examination of third-party billing logs and insurer audit history
• Review of controlled substances logs and narcotics reconciliations
• Analysis of patient privacy compliance and any past complaints
• Investigation of employee files for potential claims
• Search of court records for any litigation involving the corporation
• Environmental assessments if the corporation owns property

This due diligence takes more time, costs more money, and increases the risk of discovering problems that kill the deal or force price renegotiations.

Limited ability to restructure

After a share sale closes, the buyer owns the corporation as-is. Problematic elements are harder to unwind. Examples:

• Employees with poor performance but long tenure (severance costs)
• Unfavourable supplier contracts with penalties for termination
• Outdated pharmacy software with high switching costs
• Inefficient workflows embedded in the corporate culture
• An above-market lease committed for several more years

In an asset sale, the buyer can negotiate which employees to hire, which contracts to assume, and which systems to implement. In a share sale, everything transfers and must be managed or changed post-closing at the buyer’s expense.

Indemnity enforcement challenges

Most share purchase agreements include seller indemnities (promises to reimburse the buyer for undisclosed liabilities that surface after closing). However, enforcing these indemnities can be difficult:

• The seller may become unavailable or move assets to other entities
• If the seller sold through a holding company, that company may be wound up or emptied after closing (ask who gives the indemnity and what backs it)
• Disputes arise about whether a liability was properly disclosed
• Legal costs to pursue claims can exceed the claim value
• Sellers often negotiate caps on total indemnity exposure

Asset sales reduce many of these issues because most liabilities do not transfer in the first place, although the exceptions described earlier (continuing employees, some tax clearance matters, registered liens) still need to be managed.

Tax implications: asset sale vs share sale

Tax treatment differs significantly between the two structures, affecting both sellers and buyers. This is general information, not tax advice; the numbers for your sale must come from your accountant.

Seller’s tax position

Asset sale. Your corporation sells the assets, and different assets are taxed differently:

• Inventory: what the corporation receives above the inventory’s cost is ordinary business income
• Goodwill: generally Class 14.1 property. Depending on its cost and any capital cost allowance (CCA) claimed, part of the proceeds can be taxed as recaptured CCA (business income) and the rest as a capital gain (50% inclusion as of 2026)
• Depreciable property (equipment): may trigger recapture of CCA (taxed as income), a capital gain if sold above original cost, or a terminal loss

These amounts are taxed in your corporation first, and you pay personal tax again when you take the money out as dividends or salary. Some tools reduce that second layer (for example, the non taxable half of a capital gain can usually be paid out tax free through the capital dividend account). The result is often, but not always, a higher overall tax bill than a qualifying share sale, mainly because there are two layers of tax and the corporation cannot use your LCGE. How the purchase price is allocated among asset classes changes the answer.

Share sale. You sell your shares personally (or through a holding company), and the gain is a capital gain: 50% of the gain is included in taxable income (as of 2026), the LCGE can shelter up to $1,275,000 if your shares qualify and you have not used it, and the remainder is taxed at capital gains rates. AMT may apply in the year of sale.

Example comparison (illustrative). Sale price: $1,500,000. Original cost of the shares: $200,000. Gain: $1,300,000.

In a situation like this, a qualifying share sale can save the seller a significant amount compared with an asset sale. We do not put a single number on the asset sale side because it depends on too many facts. Ask your accountant for a side by side schedule of both structures, including price allocation, cost base, recapture, corporate and personal tax, LCGE availability and AMT, before you negotiate structure.

Buyer’s tax position

Asset sale. Buyers get a stepped-up cost base on the assets purchased. They can claim depreciation (CCA) on equipment and write off goodwill over time, and what they pay for inventory becomes their cost of goods sold, deducted as the stock is sold. This creates future tax deductions.

Share sale. Buyers get no step-up in asset values. The assets retain their historical cost base inside the corporation. This means less depreciation and fewer future tax deductions for the buyer.

As a result, buyers often value asset sales higher from a tax perspective and may be willing to pay slightly more for an asset deal (or demand a discount for a share deal).

Administrative complexity comparison

Asset sale complexity

More paperwork and third-party involvement:

• Detailed asset list and allocation of purchase price
• Lease assignment requiring landlord consent
• A pharmacy licence or accreditation for the buyer’s entity through the provincial college (licences generally do not simply transfer; in BC a change of direct owner application is due at least 30 days before the effective date, and in Ontario a purchase is treated as opening a new pharmacy, with an application due at least 45 days before opening and a new Certificate of Accreditation issued; other provinces have their own rules)
• New third-party billing agreements with insurers
• Employee transfer, or termination and rehiring (in several provinces, including BC under section 97 of the Employment Standards Act, employment of staff who continue is treated as continuous, so successor obligations follow)
• Assignment of supplier contracts
• Transfer of phone numbers, domain names, and social media accounts
• New utility accounts and municipal business licences

Timeline impact: asset sales often take slightly longer to close due to third-party consents and administrative steps.

Share sale complexity

Fewer third parties, but more due diligence:

• Share transfer documentation
• Corporate minute book updates
• Banking authority changes
• Usually less landlord and supplier involvement, although change of control clauses in leases, banner agreements and other contracts may still require consent, and college requirements for ownership changes still apply
• But far more intensive legal and financial due diligence
• Greater legal costs for the buyer’s counsel to review historical corporate records

Timeline impact: a share sale can close faster if due diligence reveals no issues, but major problems can delay or kill the deal entirely. For a stage-by-stage view of how either structure moves from listing to closing, see our guide to the pharmacy sales process and timeline.

How to negotiate transaction structure

Structure is negotiable, but both parties come to the table with clear preferences. Understanding the other side’s motivations helps you negotiate effectively.

Seller’s negotiation approach

If you strongly prefer a share sale for tax reasons:

• Be transparent about the tax benefit: Explain to the buyer that the LCGE gives you a meaningful tax saving (have your accountant quantify it), and you are willing to share some of that benefit through a price reduction or better terms.
• Offer stronger protections: Provide robust representations and warranties, longer survival periods, and higher indemnity caps to give the buyer comfort.
• Enhance due diligence cooperation: Make all corporate records immediately available, proactively disclose any issues, and allow unlimited access during due diligence.
• Consider price concessions: Reducing your asking price (for example, by $50,000 to $100,000), or offering vendor take-back financing, can make the share structure more attractive.
• Emphasize clean history: A pharmacy with zero college complaints, clean inspections, and no third-party billing issues is far less risky in a share sale.

Buyer’s negotiation approach

If you strongly prefer an asset sale:

• Explain the liability risks: Detail specific pharmacy industry risks (narcotics, privacy, billing clawbacks) that concern you as a buyer.
• Point to financing challenges: In our experience some lenders are more comfortable financing asset purchases, although lenders such as BDC finance both asset and share purchases, and terms depend on the deal. Our guide to pharmacy financing requirements in Canada explains how lenders assess these deals.
• Offer to share the tax cost: If the seller faces a large tax bill in an asset sale, consider increasing your price slightly to split the difference, but only if the business value justifies it.
• Propose structure alternatives: A hybrid approach can work, where certain assets transfer and others (like real estate) remain with the seller under a lease arrangement.
• Walk away if necessary: Asset sales are common in pharmacy deals for good reasons. If the seller insists on a share sale and will not provide adequate protections, walking away may be your best option.

Practical decision framework: which structure to choose

Choose an asset sale if:

• You are the buyer and risk mitigation is your priority
• The pharmacy has any compliance history concerns
• Third-party billing errors or clawbacks are possible
• The corporation has accumulated liabilities you want to avoid
• You want maximum flexibility to restructure operations
• Your bank requires or strongly prefers an asset purchase
• The seller’s tax situation does not create a huge differential

Choose a share sale if:

• You are the seller and qualify for the LCGE
• Your accountant’s model shows the tax savings are substantial
• Your pharmacy has a clean compliance and operational history
• You can provide strong indemnities and representations
• The buyer is sophisticated and willing to accept the structure for price concessions
• Third-party consents (lease, franchisor) might be difficult to obtain in an asset sale
• Your accountant confirms LCGE qualification and structure suitability

When structure becomes a deal-breaker

Sometimes structure preferences are so strong that deals fail. Common scenarios:

• The seller insists on a share sale to access the LCGE and the buyer refuses due to risk
• The buyer’s bank will not finance a share purchase at the required amount
• Due diligence in a share sale reveals liabilities that cause the buyer to walk away
• The landlord refuses to assign the lease in an asset sale and the buyer cannot accept this risk

In these cases, creative solutions sometimes bridge the gap:

• The seller agrees to an asset sale but the buyer increases the price to offset some of the tax cost
• The share sale proceeds but the buyer negotiates a large holdback (escrow) for 12 to 24 months to cover undisclosed liabilities
• A hybrid structure where real estate or certain assets are sold separately
• Post closing consulting or employment arrangements for real transition services at market rates (these payments are taxed as income to the seller and must not be used to relabel part of the purchase price; have a tax advisor review them)

Practical steps to prepare

For sellers (12 to 24 months before sale):

1. Meet with your accountant to confirm your corporation qualifies for the LCGE if you want a share sale.
2. Purify your corporation if needed (remove passive investments).
3. Ensure corporate records are complete and current (minute books, resolutions, share certificates).
4. Address any outstanding compliance issues, tax filings, or regulatory matters.
5. Document all liabilities clearly so you can provide full disclosure.
6. Understand your tax position in both asset and share sale scenarios.
7. Decide your structure preference and bottom-line negotiation position.

For buyers:

1. Determine your risk tolerance and structure preference.
2. Consult with your financing source about their structure preferences.
3. Engage a lawyer experienced in pharmacy transactions early.
4. Build a due diligence checklist specific to share versus asset sales.
5. Calculate the tax implications of each structure from your perspective.
6. Decide what price adjustment (if any) would make you accept a less-preferred structure.
7. Be prepared to walk away if the structure creates unacceptable risk.

Conclusion: structure matters as much as price

The difference between an asset sale and a share sale can mean a significant difference in your pocket as a seller, or reduced liability exposure as a buyer.

Neither structure is universally better. Asset sales generally give buyers more protection and often cost sellers more in tax. Share sales can save qualifying sellers tax but leave more risk with the buyer. The right answer depends on your specific situation, tax position, risk tolerance, and negotiation leverage.

What matters most is making an informed decision early in the process. Owners who wait until they have a letter of intent on their pharmacy for sale often find themselves locked into unfavourable positions or scrambling to restructure corporations at the last minute.

Work with your accountant and a pharmacy transaction lawyer at least 12 months before you plan to list your pharmacy for sale. Understand the implications of both structures. Know your preference and your walk-away point. Then negotiate from knowledge rather than confusion.

If you are planning to sell your pharmacy and need guidance on transaction structure, tax planning, and how to position your business for either an asset or share sale, our team provides comprehensive advisory services. Contact us for a confidential consultation.